Phoenicia Scientists were awarded a new US patent (8,759,378, Issued June 24, 2014: “Methods for Treating Blood Disorders”), covering newly-discovered small molecules which regulate fetal globin production for the treatment of β-thalassemia and sickle cell disease
NIH grant to convert a potent IV
therapy for refractory wounds into
a topical formulation
Phoenicia has received a new small business grant from the National Institutes of Health for studies to convert an intravenous therapy which healed refractory, disabling leg ulcers in hemolytic anemias, sickle cell disease and β-thalassemia, into a topical preparation which can be used readily by patients world-wide. Continue reading
The mission of Phoenicia Biosciences is to advance the development and translation of therapies for serious medical conditions for which current treatments are inadequate or lacking, particularly diseases affecting global populations.